Drugs / Shengbai
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07578064 | Aug 2025 → Sep 2026 overdue | bone marrow disorder, breast cancer | Hongxia Wang | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shengbai | “they took Shengbai Oral Liquid (40 ml, three times a day)” NCT07578064 ↗ |
| Route | Oral | “they took Shengbai Oral Liquid (40 ml, three times a day)” NCT07578064 ↗ |